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Edited by Jesus AvilaAbstract Insoluble deposits of tau and amyloid precursor pro-
tein (APP) peptides Ab characterize Alzheimers disease. We
studied the role of tau in the metabolism of APP in cells stably
expressing APP Swedish mutation (CHOsw). Transient expres-
sion of tau in CHOsw cells caused morphological changes,
bundling of microtubules and perinuclear aggregation of Golgi-
derived vesicles. It also reduced the secretion of Ab1–40 and
Ab1–42 without altering the APP steady state levels. This was
accompanied by a reduction in the c-secretase and an increase
in the insulin degrading enzyme activities. Our results suggest
that tau may play an inhibitory role in the amyloidogenic activity
of APP.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Adenovirus1. Introduction
Alzheimers disease (AD) is characterized by two neuro-
pathological hallmarks, neuroﬁbrillary tangles composed of
tau protein aggregates and amyloid plaques composed of
ﬁbrillary Ab peptides (Ab). The relationship between these
two biomarkers remains unclear. Less than 5% of all AD cases
are early onset familial AD attributed to genetic abnormalities
in three genes: presenilin 1 (3–4%), presenilin 2 (1%), and amy-
loid precursor protein (APP, 0.5%). The majority of AD
cases (95%) are sporadic and their cause is unknown. The com-
monality of tau abnormalities in neurodegenerative disorders
strongly suggests that tau dysregulation may be involved in
the development of sporadic AD.
Ab consists mainly of the 40–42 amino acid peptides (Ab1–40
and Ab1–42) generated by a sequential proteolytic cleavage of
APP by b-secretase and c-secretase [1]. First, b-secretase yields
a 10-kDa C-terminal APP fragment. Further processing by c-Abbreviations: AD, Alzheimers disease; APP, amyloid precursor
protein; CHO cells, Chinese hamster ovary cells; CTF, C-terminal
fragment; IDE, insulin degrading enzyme; LacZ, b-Galactosidase;
MOI, multiplicity of infectious viral particles; MTT, 3-[4,5-dimethyl-
thiazol-2-yl]-2,5 diphenyltetrazolium bromide
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doi:10.1016/j.febslet.2005.02.067secretase yields two major Ab species, Ab1–40 and less abun-
dant and less soluble Ab1–42. Gamma-secretase is a proteolytic
complex associated with presenilin and other protein compo-
nents in the Golgi/trans-Golgi network [2,3]. The subsequent
degradation and clearance of Ab are performed among others
by insulin degrading enzyme (IDE), a zinc metallo-peptidase
localized mostly in cytosol and also found in plasma mem-
brane and internal membranes at sites of Ab generation [4].
The early onset familial AD mutations in the presenilin genes
alter the c-secretase activity or its access to the substrate and
disturb the ratio of the two Ab peptides [5].
Tau is a microtubule associated protein which plays a role in
stabilization of microtubules and traﬃcking of organelles [6].
Overexpression of tau has been found to inhibit kinesin-depen-
dent traﬃcking of APP vesicles in cultured neurons [7]. Tau is
involved in the maintenance of the Golgi organization [8]. The
role of tau in the metabolism of APP and Ab production has
not been fully examined.
Chinese hamster ovary (CHO) cells have been engineered [9]
to stably express the APP double mutation (codons 670/671)
prevalent in two Swedish families (CHOsw). We found that
tau-expressing CHOsw cells had speciﬁcally reduced the c-
secretase activity and a reduced secretion of both Ab1–40 and
Ab1–42 to the media. The results are consistent with tau playing
an inhibitory role in the amyloidogenic activity of APP.2. Materials and methods
2.1. Adeno-X expression virus construction and cell cultures
The human tau clone htau24 was used to generate htau24 cDNA in
pBluescript. The replication-defective recombinant adeno-expression
virus expressing htau24 or b-galactosidase (LacZ) was generated and
packaged using AdenoX expression system following manufacturers
directions (Clontech) as described [10]. The viral titer was deﬁned as
multiplicity of infectious viral particles (MOI). The CHOsw cells were
cultured in Dulbeccos modiﬁed Eagles medium supplemented with
10% fetal calf serum (Gibco). Cells were seeded at the density of
1.5 · 104 cells/cm2 and cultured in a 5% CO2 incubator at 37 C for
24 h to reach 50% conﬂuency. The eﬃciency of infections at 5 MOI
was 70–95% based on the number of LacZ-positive cells at 24 and
48 h post-infection.2.2. Western blotting and immunoﬂuorescence
CHOsw were seeded onto 12-well plates and collected 24 or 48 h
post-infection. For Western blotting analysis, cells were lysed in so-
dium dodecyl sulfate-loading buﬀer and subjected to polyacrylamide
gel electrophoresis followed by electrotransfer onto nitrocellulose
membrane. Speciﬁc protein signals on Western blots were detected
using peroxidase-conjugated secondary antibodies and supersignal
substrate mixture (Pierce), and quantiﬁed by Bioquant (Bio-Rad Lab-blished by Elsevier B.V. All rights reserved.
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noﬂuorescence, cells were seeded in Lab Trek II chamber slides, ﬁxed
with 0.3% glutaraldehyde in full culture medium for 10 min at 37 C,
and stained as previously described [10]. Digital images were obtained
using Zeiss Axioskop microscope. The primary antibodies included the
total tau antibody Tau 46 (Zymed), the phospho-tau antibody PHF-1
(pSer396/404), phospho-tau antibodies AT8 (pSer202/205) and AT100
(pThr212/pSer214) (Innogenetics), and anti-actin and anti-b-tubulin
antibodies (Sigma). Anti-IDE antibody was from Covance, NJ. Total
human holo-APP was detected using the polyclonal antibody C8 raised
against amino acids 676–695 of human APP. The monoclonal anti-
body 22C11 (Chemical Int., CA) detects the N-terminus of human
APP between amino acids 60–100 and was used to quantify total sol-
uble (s)APP released into the cultured medium. The monoclonal anti-
body 6E10 (Senetek, MO) recognizes amino acids 1–17 of the Ab
domain in the C-terminus of APP fragment (APPa) generated
a-secretase. It was used to quantify the levels of sAPPa released to
the culture medium. Golgi-derived vesicles were visualized with rhoda-
mine labeled wheat germ agglutinin (WGA; Vector Labs).
2.3. MTT and TUNEL assays
CHOsw were seeded at the density 1 · 104/well onto 96-well plates
and subjected to viability assay using 3-[4,5-dimethylthiazol-2-yl]-2,5
diphenyltetrazolium bromide (MTT) [10]. For TUNEL assay, CHOsw
were seeded at 3 · 104/well onto Lab Trek II chamber slides. Slides
were ﬁxed in ice-cold 100% ethanol and processed using Apotag in
situ apoptosis detection kit (Intergen). The TUNEL positive cells were
quantiﬁed using Bioquant.
2.4. Secretion of Ab
Conditioned media from CHOsw cultures were centrifuged to re-
move cellular debris and analyzed for the Ab1–40 or Ab1–42 content
by ELISA, as recommended by the manufacturer (BioSource, Cama-
rillo, CA).
2.5. Cell membrane fraction
Brieﬂy, CHOsw cell monolayers were rinsed and collected in cold
phosphate buﬀered saline. Cell pellets were resuspended in the homog-
enization buﬀer (0.5 ml/10 cm ;dish) containing 10 mM MOPS,
pH 7.0, 10 mMKCl and 1· complete protease inhibitor mixture (Roche
Molecular Biochemicals, Germany). The homogenates were centri-
fuged (2500 rpm, 15 min at 4 C) to remove unbroken cells and nuclei.
The post-nuclear supernatant was centrifuged (14000 rpm, 20 min at
4 C) and the pellet washed in the homogenization buﬀer. The ﬁnal pel-
let was resuspended in the c-secretase or IDE assay buﬀers.
2.6. Gamma-secretase activity
To assess the c-secretase activity, the content of C-terminal frag-
ment (CTF)-c cleavage product of APP was determined in prepara-
tions of cell membranes as described in [11]. Cell membrane pellets
were suspended in 50 ll assay buﬀer (150 mM sodium citrate, pH
6.4, with 1· protease inhibitor mixture). One half of the sample
was incubated for 2 h at 37 C to generate the CTF-c cleavage prod-
uct, the other half was maintained on ice for negative control. CTF-
c (as well as CTF-a and CTF-b) cleavage products were resolved in
10–20% gradient polyacrylamide gels (Bio-Rad) and quantiﬁed using
Western blot analysis.2.7. IDE content and activity
Cell membrane fractions were resuspended in HEPES buﬀer (50 mM
HEPES, pH 7.4, 100 mM NaCl, and 1 ll/ml protease inhibitor mix-
ture, Sigma). The enzymatic reaction was carried out using 40 lg mem-
brane fraction in 100 ll reaction buﬀer containing 50 mM HEPES
buﬀer, pH 7.5, 1% bovine serum albumin and 300 pM (10000 cpm)
[I125] insulin (Amersham) as a substrate [12]. Samples were incubated
for 0–2 h at 37 C and the reaction terminated by the addition of
1 ml of 5% trichloroacetic acid. Samples were centrifuged at
14000 · g for 10 min at 4 C to obtain the pellet containing undigested
substrate and the supernatant containing degraded product. I125 radio-
activity in both fractions was quantiﬁed using gamma-scintillation
counter. The IDE activity was calculated as the percent of I125-radio-
active material released to the supernatant. The IDE content was
quantiﬁed using Western blot analysis.3. Results
3.1. Adenoviral expression of tau is non-toxic at 5 MOI
To assess the cytotoxic response, CHOsw cells were infected
with adeno-tau (tau) or adeno-LacZ (LacZ) viral constructs at
loads of 5, 10 and 20 MOI and examined 24 and 48 h post-
infection. With tau, only 5 MOI load showed no detectable
toxicity by MTT, whereas 10 and 20 MOI loads were cytotoxic
at 48 h post-infection as compared to LacZ (not shown). Con-
sistent with the MTT evidence, the number of apoptotic cells
determined by TUNEL remained at control level in cultures
infected with 5 MOI but increased in cultures infected with
10 and 20 MOI for 24 and 48 h (not shown).3.2. Expressed tau is phosphorylated
The endogenous tau content was below detection by Wes-
tern blotting (Fig. 1A) as noted previously by others [13].
CHOsw cells infected with adeno-tau under non-toxic condi-
tions (5 MOI) expressed tau as early as 24 h post-infection.
Immunoblotting studies revealed that expressed tau was phos-
phorylated at several phospho-epitopes (Fig. 1A). These in-
cluded the PHF-1 and AT8 epitopes, as well as the AT100
epitope, highly speciﬁc to AD brain.3.3. Expression of tau changes cell morphology and localization
of Golgi elements
Non-infected and LacZ-expressing CHOsw cells showed a
similar morphology. Both were either ﬂat or elongated
in their morphological appearance, with well-developed
microtubule network around nucleus, in the microtubule
organizing center and in cell processes (Fig. 1B, green).
Mitochondria were detected in perinuclear clusters as well
as along the microtubules in cell processes (Fig. 1B, red).
Tau-expressing cells appeared rounded in their morphology
(Fig. 1C, green; Fig. 2D). They displayed a circular microtu-
bule network under the plasma membrane, suggesting bun-
dling of microtubules. Changes in the distribution of
mitochondria were not evident except for a more diﬀused
localization (Fig. 1C, red). Staining for total tau revealed
an intensely tau-positive cell interior (Fig. 2D). In the major-
ity of cells, tau staining was most prominent in the perinu-
clear region. Cells were characterized by irregular ameba-like
projections of the cell membrane (Fig. 2D, arrowhead), sug-
gesting changes in the membrane structure or membrane-
associated cytoskeleton.
In non-infected and LacZ-expressing cells, Golgi-derived
vesicles were most prominent in the perinuclear region, consis-
tent with the localization of the Golgi complex and the micro-
tubule organizing center (Fig. 2B and C). They were also seen
in the cell body and cell processes, arranged into distinct arrays
most likely alongside the microtubule tracks. In tau infected
cells, Golgi-derived vesicles were highly concentrated around
the nucleus, forming a large aggregate in some cells (Fig. 2E
and F, white arrows). Individual vesicles were diﬃcult to dis-
tinguish. The aggregated Golgi elements and tau showed a lim-
ited co-localization.3.4. Secretion of Ab is reduced
We monitored Ab levels in the cultured media of CHOsw
cells using ELISA assays speciﬁc for Ab1–40 and Ab1–42.
Tau-expressing CHOsw cells showed a reduced secretion of
Fig. 2. Immunocytochemistry of tau-expressing CHOsw cells. Cells were infected with adeno-LacZ (A–C) or adeno-tau (D–F) viral constructs at 5
MOI. Cells were ﬁxed 24 h post-infection and stained for total tau (Tau 46), Golgi-derived vesicles (rhodamine labeled WGA), nuclei (DAPI) or
merged as indicated. In (D), white arrowhead denotes tau-positive cell membrane projections. In (E) and (F), note large aggregates of Golgi-derived
vesicles (white arrows).
Fig. 1. Characterization of CHOswe cell cultures. (A) Western blotting of CHOsw lysates (35 lg) collected 24 h post-infection. Blots were stripped
and re-probed for total tau (Tau 46), AD-speciﬁc phosphoepitope (AT100), phosphorylated tau (PHF-1, AT8) or actin as internal standard. Results
from three cultures in each group are presented. (B and C) Cells were infected either with adeno-LacZ or adeno-tau at 5 MOI, respectively, and
stained for b-tubulin (FITC) 24 h post-infection. Cells were incubated with MitoTracker Red (CMXRos) for 30 min prior ﬁxation to label
mitochondria.
Z. Zhao et al. / FEBS Letters 579 (2005) 2119–2124 2121both Ab1–40 and Ab1–42 to the media as compared to LacZ-
expressing cells (Fig. 3). The reduction by 24–36% was noted
as early as 24 h post-infection and persisted for 48 h.
3.5. Holo-APP is unchanged
Steady state intracellular levels of holo-APP were monitored
using antibodies raised against the N-terminus (22C11) and C-
terminus (C8) of total APP. Extracellular levels of sAPP were
monitored using 6E10 and 22C11 antibodies and the obtained
ratio of 6E10 to 22C11 immunoreactivity was an indicator of
sAPPa production. We found that CHOsw cells infected with
5 MOI adeno-tau for 24 and 48 h showed no alterations in the
intracellular (Fig. 4A and B) and extracellular levels of APP(Fig. 4C) relative to LacZ. These results suggest that changes
in the steady state levels of APP are not responsible for the
reduced secretion of Ab. The distribution of holo-APP in
CHOsw cells appeared unaﬀected by tau transfections as
determined by immunocytochemistry with the C8 antibody
(Fig. 5). In cells expressing either LacZ or tau, the staining
for total APP was granular with an apparent concentration
around the nucleus and more diﬀuse pattern at the periphery.
3.6. Gamma-secretase is reduced and IDE is upregulated
We assessed the activity of c-secretase and IDE, two prote-
olytic enzymes involved in the generation and clearance of
Ab, respectively. Preparations of membrane fraction from
Fig. 4. APP levels in cells and media. (A and B) Quantitative Western blot analysis of holo-APP in cell lysates detected with 22C11 (N-terminus) and
C8 (C-terminus) antibodies. Results are expressed in % of LacZ and represent means ± S.E.M. (n = 3). Inset: selected Western blots. (C) Soluble APP
(sAPP) levels in the conditioned CHOsw media detected by Western blotting. Viral load is 5 MOI. Values are means ± S.E.M. (n = 3).
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Fig. 3. Secretion of Ab1–40 and Ab1–42 into the CHOsw media. Viral load was 5 MOI. Values represent means ± S.E.M. for three separate
experiments using three cultures each. \P < 0.05, \\P < 0.005 vs LacZ.
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reduced (by 33%) c-secretase activity at 24 h but not 48 h as
evaluated by the generation of CTF-c cleavage product (Fig.
6A). On the other hand, the IDE content and activity showed
a signiﬁcant elevation at 24 h but not 48 h post-infection (Fig.
6B and C). The results suggest that both the decrease in c-
secretase activity and increases in IDE content and activity
could contribute to the reduced secretion of Ab in tau-express-
ing CHOsw cells.4. Discussion
In the present studies, we found that expression of tau had
an impact on metabolism of APP in CHOsw cells. Speciﬁcally,
it reduced the secretion of Ab1–40 and Ab1–42 to the media inthe absence of changes in the steady state level of APP. It also
reduced the c-secretase activity and elevated both the IDE
activity and content in the membrane fraction. Our data
strongly suggest that expression of tau plays an inhibitory role
in the amyloidogenic activity of APP.
The mechanisms could involve interference of tau with the
microtubule function, especially that related to the transport
of APP vesicles, APP turnover and/or endo/exocytosis of Ab.
Previous studies have shown that transient expression of tau
in diﬀerentiated neuroblastoma N2a cells stably overexpress-
ing APP695 inhibits kinesin-dependent transport of APP-con-
taining vesicles into axons and dendrites [7]. Such inhibition
induces accumulation of APP in N2a cell bodies detected by
immunocytochemistry. In the present studies, adenoviral
expression of tau in non-neuronal CHOsw cells altered cell
morphology from elongated to rounded, caused bundling of
Fig. 5. Distribution of holo-APP in tau-expressing CHOsw cells. Cells were infected with adeno-LacZ (A–C) or adeno-tau (D–F) viral constructs at 5
MOI. Cells were ﬁxed 24 h post-infection and stained for holo-APP (C8), phospho-tau (PHF-1), nuclei (DAPI) or merged as indicated. Note a similar
distribution of APP in LacZ- or tau-expressing cells.
Fig. 6. Gamma-secretase and IDE activities in CHOsw membrane preparations. (A) Western blotting and quantitative analysis of APP CTF-c
cleavage products generated by c-secretase. The results are normalized with holo-APP. Values represent means ± S.E.M. for three independent
experiments and three preparations per experiment. Inset: examples of Western blots. (B and C) IDE content and activity determined per 40 lg
membrane fractions using [I125] insulin as substrate. Inset: examples of Western blots. Viral load is 5 MOI. Values represent means ± S.E.M. (n = 3).
\P < 0.05 vs LacZ.
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vesicles. These ﬁndings indicate that expression of tau indeed
disrupted transport-related microtubule function. This could
slow down transport of Golgi-derived APP vesicles and cause
accumulation of APP. Our studies, however, detected no alter-
ations in the steady state APP content suggesting that inhibi-
tion of transport of APP-containing vesicles might have little
eﬀect on net accumulation of APP in cells. This conclusion is
additionally supported by an absence of apparent alterations
in the intracellular distribution of APP under these conditions.
Tau-expressing cells showed a diminished secretion of
Ab1–40 and Ab1–42 to the media. This could be a direct result
of slower dynamics of APP cleavage due to partially inhibited
c-secretase activity. It could also result from a more eﬀective
clearance of Ab by IDE, since both the content and activity
of IDE were found upregulated in the membrane fraction. It
is likely that both pathways contributed to a diminished secre-
tion of Ab peptides. Additional mechanisms could involve
inhibitory eﬀects of tau on endo/exocytosis of Ab due to a
reduction of anterograde transport of Golgi-derived vesicles.
In fact, such reduction could also play a role in alterations
of c-secretase activity and membrane localization of IDE in
tau-expressing cells. A signiﬁcant fraction of c-secretase resides
in lipid rafts of post-Golgi [14]. The regulation of IDE activity,
however, or its cytosol/membrane localization is essentially un-
known. It may be relevant that most signiﬁcant changes in the
secretion of Ab and activity of processing enzymes were noted
24 h post-infection, with the initial dynamic expression of tau,
and reaching steady state levels at 48 h.
Our ﬁndings have several implications for AD. The most
intriguing is that tau may lower amyloidogenic activity in cells
expressing APP. Since AD is characterized by accelerated amy-
loid deposition in the brain, this could be of beneﬁcial value as
an alternative to a passive amyloid therapy studied in trans-
genic mice [15]. The eﬀects of tau described in the present
studies are consistent with the protective role of microtubule-
stabilizing agents reported recently in Ab-induced neurotox-
icity [16]. At present, the role of tau as a mediator of Ab
neurotoxic eﬀects in AD remains unclear.
We could speculate that a lowering of tau content in APP-
and tau-expressing cells may stimulate Ab production. A re-
duced content of soluble tau has been reported in AD and
attributed to a depletion of cytoplasmic tau into insoluble
ﬁbrillary tau deposits [17,18]. Diminished soluble tau content
in AD could additionally accelerate Ab production and AD
neuropathology.
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